Literature DB >> 11390453

Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22.

L Dumoutier1, D Lejeune, D Colau, J C Renauld.   

Abstract

The class II cytokine receptor family includes the receptors for IFN-alphabeta, IFN-gamma, IL-10, and IL-10-related T cell-derived inducible factor/IL-22. By screening genomic DNA databases, we identified a gene encoding a protein of 231 aa, showing 33 and 34% amino acid identity with the extracellular domains of the IL-22 receptor and of the IL-20R/cytokine receptor family 2-8, respectively, but lacking the transmembrane and cytoplasmic domains. A lower but significant sequence identity was found with other members of this family such as the IL-10R (29%), cytokine receptor family 2-4/IL-10Rbeta (30%), tissue factor (26%), and the four IFN receptor chains (23-25%). This gene is located on chromosome 6q24, at 35 kb from the IFNGR1 gene, and is expressed in various tissues with maximal expression in breast, lungs, and colon. The recombinant protein was found to bind IL-10-related T cell-derived inducible factor/IL-22, and to inhibit the activity of this cytokine on hepatocytes and intestinal epithelial cells. We propose to name this natural cytokine antagonist IL-22BP for IL-22 binding protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11390453     DOI: 10.4049/jimmunol.166.12.7090

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  84 in total

Review 1.  Structure and function of interleukin-22 and other members of the interleukin-10 family.

Authors:  Daniela Barretto Barbosa Trivella; José Ribamar Ferreira-Júnior; Laure Dumoutier; Jean-Christophe Renauld; Igor Polikarpov
Journal:  Cell Mol Life Sci       Date:  2010-05-08       Impact factor: 9.261

2.  Membrane-bound IL-22 after de novo production in tuberculosis and anti-Mycobacterium tuberculosis effector function of IL-22+ CD4+ T cells.

Authors:  Gucheng Zeng; Crystal Y Chen; Dan Huang; Shuyu Yao; Richard C Wang; Zheng W Chen
Journal:  J Immunol       Date:  2011-06-01       Impact factor: 5.422

3.  Donor interleukin-22 and host type I interferon signaling pathway participate in intestinal graft-versus-host disease via STAT1 activation and CXCL10.

Authors:  B Lamarthée; F Malard; C Gamonet; C Bossard; M Couturier; J-C Renauld; M Mohty; P Saas; B Gaugler
Journal:  Mucosal Immunol       Date:  2015-07-08       Impact factor: 7.313

4.  Structure of IL-22 bound to its high-affinity IL-22R1 chain.

Authors:  Brandi C Jones; Naomi J Logsdon; Mark R Walter
Journal:  Structure       Date:  2008-07-03       Impact factor: 5.006

Review 5.  Cytokine crowdsourcing: multicellular production of TH17-associated cytokines.

Authors:  Kathleen O Busman-Sahay; Travis Walrath; Samuel Huber; William O'Connor
Journal:  J Leukoc Biol       Date:  2014-12-29       Impact factor: 4.962

Review 6.  Structure of interleukin-10/interleukin-10R1 complex: a paradigm for class 2 cytokine activation.

Authors:  Mark R Walter
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

7.  Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue.

Authors:  Tiffany Hughes; Brian Becknell; Aharon G Freud; Susan McClory; Edward Briercheck; Jianhua Yu; Charlene Mao; Chiara Giovenzana; Gerard Nuovo; Lai Wei; Xiaoli Zhang; Mikhail A Gavrilin; Mark D Wewers; Michael A Caligiuri
Journal:  Immunity       Date:  2010-06-25       Impact factor: 31.745

8.  All of the twos, 22-bingo!

Authors:  Andrew J Rees
Journal:  J Am Soc Nephrol       Date:  2014-03-07       Impact factor: 10.121

Review 9.  IL-22 in tissue-protective therapy.

Authors:  Heiko Mühl; Patrick Scheiermann; Malte Bachmann; Lorena Härdle; Anika Heinrichs; Josef Pfeilschifter
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

10.  Association between CXCR2 and IL-22BP expression indicate a poor outcome for gastric adenocarcinoma progression.

Authors:  Shi Bin Yang; Fanghai Han; Jian Hai Wu; Zhi Zhao; Wenhua Zhan
Journal:  Oncol Lett       Date:  2016-06-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.